Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109210 | 0.88 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2MKNK1MKNK2FGFR1 | |
| SCHEMBL5117930 | 0.87 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MKNK1MKNK2JAK1 | |
| SCHEMBL5119140 | 0.86 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5108869 | 0.83 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29623632 | 0.74 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MKNK1MKNK2FGFR1 | |
| SCHEMBL20603935 | 0.74 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MKNK1MKNK2FGFR1 | |
| SCHEMBL5119139 | 0.74 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14218511 | 0.74 | RIPK1 (0.39) | ALDH1A1SMN1; SMN2MKNK1MKNK2 | |
| SCHEMBL5113159 | 0.73 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5108864 | 0.73 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609656-B2 | Heteroarylphenylurea derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1724258-A1 | HETEROARYLPHENYLUREA DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHRM1, CBR3, CHRM2 | ALDH1A1 1053/4885SMN1; SMN2 3265/4885MKNK1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.